tiprankstipranks
Advertisement
Advertisement
Simulations Plus Posts Mixed Q1 2026 Results, Reaffirms Outlook
PremiumCompany AnnouncementsSimulations Plus Posts Mixed Q1 2026 Results, Reaffirms Outlook
2M ago
Simulations Plus reports Q1 adjusted EPS 13c, consensus 20c
Premium
The Fly
Simulations Plus reports Q1 adjusted EPS 13c, consensus 20c
2M ago
Simulations Plus backs FY26 adjusted EPS view $1.03-$1.10, consensus $1.03
Premium
The Fly
Simulations Plus backs FY26 adjusted EPS view $1.03-$1.10, consensus $1.03
2M ago
Simulations Plus Announces New Executive Appointments
PremiumCompany AnnouncementsSimulations Plus Announces New Executive Appointments
3M ago
FDA guides on streamlined nonclinical monoclonal antibody safety studies
Premium
The Fly
FDA guides on streamlined nonclinical monoclonal antibody safety studies
4M ago
Positive Outlook for Simulations Plus Amid Strong Financial Performance and Strategic Industry Alignment
Premium
Ratings
Positive Outlook for Simulations Plus Amid Strong Financial Performance and Strategic Industry Alignment
4M ago
Strong Q4 Results and Promising 2026 Outlook Drive Buy Rating for Simulations Plus
PremiumRatingsStrong Q4 Results and Promising 2026 Outlook Drive Buy Rating for Simulations Plus
5M ago
Simulations Plus Announces Fiscal 2025 Results and 2026 Guidance
Premium
Company Announcements
Simulations Plus Announces Fiscal 2025 Results and 2026 Guidance
5M ago
Simulations Plus sees FY26 adjusted EPS $1.03-$1.10, consensus 87c
Premium
The Fly
Simulations Plus sees FY26 adjusted EPS $1.03-$1.10, consensus 87c
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100